Implantica to Unveil Year-End Report for Q4 2025 on February 25, 2026

Implantica's Year-End Report Presentation for Q4 2025

Implantica AG, a prominent name in the medtech arena, is all set to present its Year-End Report for the fourth quarter of 2025 on February 25, 2026, at 15:00 CET. This awaited presentation offers investors a key insight into the company’s financial health and strategic direction. The report will be publicly available starting at 08:00 AM CET on the same day, setting the stage for an engaging discourse later in the afternoon.

The annual presentation is critical as it not only covers financial outcomes but also explores operational developments and future projections, crucial for stakeholders. Implantica's leadership team, including CEO Peter Forsell, CFO Andreas Öhrnberg, and Chief Corporate Affairs Officer Nicole Pehrsson, will address participants directly. The engagement will be designed for both in-person attendance via a webcast and teleconference options, reflecting the company’s commitment to accessibility and investor engagement.

To join the webcast, potential attendees can follow this link, ensuring real-time access to the latest company updates. For those wishing to engage through teleconference, registration is necessary. Participants will receive the relevant phone number and conference ID upon successful registration through this link.

Implantica has made significant strides with its flagship product, RefluxStop®, an innovative implant designed for the prevention of gastroesophageal reflux. This device has the potential to revolutionize how reflux conditions are treated, as indicated by successful clinical trial results. Furthermore, the company has ambitious plans for growth in the realm of eHealth, leveraging technology to enhance patient monitoring and treatment.

The 2025 report is expected to highlight key accomplishments over the past year and provide orientation on upcoming initiatives, particularly around the company’s patented eHealth platform that aims to monitor health parameters and manage treatments remotely.

As Implantica prepares for this significant event, investors are urged not to miss this opportunity to gain valuable insights into the company’s future direction. For additional inquiries or more information, interested parties can reach out to Nicole Pehrsson at Investor Relations via phone at +41 43 505 20 57 or through email.

Implantica is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker IMP A SDB). This ongoing emphasis on transparency, particularly in financial disclosures, underscores the company’s commitment to shareholder value and accountability. With the medtech landscape rapidly evolving, this presentation serves as a pivotal moment for both Implantica and its investors as they look forward to new opportunities ahead.